Is Wave Life Sciences Ltd. overvalued or undervalued?

As of 16 March 2017, the valuation grade for Wave Life Sciences Ltd. has moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a price-to-book value of 6.19, an EV to EBITDA of -7.50, and a return on equity (ROE) of -62.52%. These figures indicate significant financial distress and a lack of profitability.
When compared to peers, Wave Life Sciences Ltd. shows a less favorable position; for instance, Adaptive Biotechnologies Corp. has a P/E ratio of -11.52 and an EV to EBITDA of -12.80, while Novavax, Inc. stands out with a P/E ratio of 2.15 and an EV to EBITDA of 1.04. The company's recent stock performance has been volatile, with a year-to-date return of -43.73%, contrasting sharply with the S&P 500's 2.44% gain, further reinforcing the notion that Wave Life Sciences Ltd. is overvalued in its current state.